Divi’s Laboratories Share Price Hits a Record High, Up 84% This Year: Buy, Sell or Hold After the Q2 FY27 Profit Jump?
- November 9, 2026
- Posted by: Ankit Jaiswal
- Category: News
Divi’s Labs hit a record high on 9 Nov 2026 (Mint). Q2 FY27 PAT Rs 1,127 crore, up 63.6%; EBITDA margin 42.6%. Business Standard: market cap above Rs 3 trillion.
Quick Answer
The Divi’s Laboratories share price hit a record high on 9 November 2026, up about 84% this year according to Mint, after Q2 FY27 profit rose 64% to Rs 1,127 crore and EBITDA margin widened to 42.6%. Business Standard reported a 15% rally in two days and a market cap above Rs 3 trillion, so valuation is now the central question.
The Divi’s Laboratories share price hit a record high on 9 November 2026, and Mint asks whether to buy, sell or hold. Univest does not recommend securities, so this article sets out the Q2 FY27 numbers, what drove them, how the valuation and analyst opinions look, and what to check before deciding. Figures are attributed and time-stamped, and I have no live quote.
Click Here – Get Free Investment Predictions
Divi's Laboratories Share Price: The Record High in Context
| Divi’s Laboratories share price: item | Reading | Source |
|---|---|---|
| Event | Record high on 9 November 2026 | Mint headline |
| Year-to-date gain | About 84% | Mint headline |
| Rally after results | About 15% in two sessions | Business Standard, 9 November |
| Market capitalisation | Crossed Rs 3 trillion for the first time | Business Standard, 9 November |
| Earlier peak after Q1 FY27 | Rs 8,464 on 4 August 2026 | Press reports |
A rally of this size in two sessions means the Divi’s Laboratories share price has priced in a lot of good news quickly. On the Q1 FY27 earnings per share of Rs 33.95 and profit of Rs 902 crore, the share count works out at about 26.57 crore (my arithmetic), so a Rs 3 trillion market cap implies a price near Rs 11,300 (my rough arithmetic, not a quote). Check the live price and the Nifty 50 backdrop.
Divi's Laboratories Q2 FY27 Results: What Drove the Record High
| Divi’s Labs Q2 FY27: metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from operations | Rs 3,676 crore | About Rs 2,715 crore | Up 35.4% |
| Total income | Rs 3,770 crore | About Rs 2,860 crore | Up about 32% |
| EBITDA | Rs 1,566 crore | Rs 888 crore | Up 76.4% |
| EBITDA margin | 42.6% | About 32.7% | Up 989 basis points |
| Profit before tax | Rs 1,505 crore | Rs 912 crore | Up about 65% |
| Net profit | Rs 1,127 crore | Rs 689 crore | Up 63.6% |
The board approved the results on 7 November 2026, and the earnings call was held at 2:00 PM IST that day. Business Standard attributed the margin gain to a higher custom synthesis contribution and better gross margins. It also noted that the custom synthesis jump came partly from shipping validation batches to customers; whether that repeats is a question for the call transcript, my reading rather than a company guarantee.
Screen pharma stocks by margin and growth on the Univest Screener
Divi's Laboratories Share Price at a Record High: Valuation and Analyst Views
| Valuation or opinion check | Reading | Source and date |
|---|---|---|
| Earlier valuation caution | About 60 times FY27 earnings estimates | Business Standard, November 2025 |
| Analyst split | Of 33 analysts, 16 Buy, 7 Hold and 10 Sell | askfuzz citing Business Standard, August 2026 |
| Consensus rating | 13 Buy, 6 Hold and 10 Sell; Neutral | Investing.com summary |
| Target range | Rs 5,610 to Rs 9,450 | Brokerage notes, before the latest rally |
| Book value multiple | About 15.2 times | Screener, before the rally |
Most published targets pre-date the rally, so several sit below the new price; that is my observation, and brokerages may revise after Q2. The split between Buy and Sell ratings shows that analysts disagreed even before the record high. A premium valuation can persist while growth continues, but it leaves less room for a miss.
Download the Univest iOS App or Univest Android App to follow pharma stocks and results alerts.
Buy, Sell or Hold the Divi's Laboratories Share Price: A Neutral Framework
| Question | What to look at |
|---|---|
| Is growth sustainable at this Divi’s Laboratories share price? | Custom synthesis order book and repeat orders, not one-off validation batches |
| Is the margin repeatable at a record high? | 42.6% is far above the 30% to 33% range of the past year |
| What is priced into the Divi’s Laboratories share price? | Compare the price with earnings estimates after Q2 revisions |
| What is your time frame? | A short trade and a multi-year holding carry different risks |
| What is your position size at a record high? | A record high after a 15% rally argues for sizing carefully |
This is a framework and not a recommendation. Each investor’s answer depends on goals, existing exposure and risk tolerance, and a SEBI-registered adviser can help with that.
Conclusion
The Divi’s Laboratories share price reached a record high on a 64% jump in Q2 FY27 profit and a 42.6% EBITDA margin, and the market cap crossed Rs 3 trillion. The numbers are strong, but valuation and the sustainability of the margin are the open questions, and analysts were split before the rally. Read the transcript, check estimates and consult a SEBI-registered adviser.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on the Divi's Laboratories Share Price
Why did the Divi's Laboratories share price hit a record high?
Ans. Mint reported a record high on 9 November 2026 after Q2 FY27 results showed net profit up 63.6% to Rs 1,127 crore, revenue from operations up 35.4% to Rs 3,676 crore and an EBITDA margin of 42.6%. Business Standard added that the stock rallied about 15% in two sessions.
What were Divi's Laboratories' Q2 FY27 results?
Ans. Net profit was Rs 1,127 crore against Rs 689 crore, EBITDA was Rs 1,566 crore, up 76.4%, and profit before tax was Rs 1,505 crore against Rs 912 crore. Total income was Rs 3,770 crore. The board approved the results on 7 November 2026.
Is the 84% rise in the Divi's Laboratories share price this year accurate?
Ans. The 84% year-to-date figure comes from the Mint headline. I did not recompute it from a start-of-year price, so verify it against a price chart. It is a headline number, not a Univest calculation.
Is the Divi's Laboratories share price expensive?
Ans. Valuation was already flagged as stretched before the rally. Business Standard noted about 60 times FY27 earnings estimates in November 2025, and Screener showed a book value multiple of about 15.2 before the latest move. Estimates have risen since, so the current multiple should be recomputed on live data.
What do analysts say about the Divi's Laboratories share price?
Ans. Opinions are split. One August 2026 count of 33 analysts showed 16 Buy, 7 Hold and 10 Sell, and Investing.com showed 13 Buy, 6 Hold and 10 Sell. Targets in my sources ranged from Rs 5,610 to Rs 9,450 and pre-date the latest rally.
Was the margin jump behind the Divi's Laboratories share price record high a one-off?
Ans. Business Standard linked the margin gain to a higher custom synthesis contribution and better gross margins, and noted validation batches shipped to customers. Whether that level repeats is unclear. The Q1 FY27 margin was 40.7% and the Q2 FY27 margin was 42.6%, so two quarters are above 40%.
What is the market cap of Divi's Laboratories at the record high?
Ans. Business Standard reported that it crossed Rs 3 trillion for the first time on 9 November 2026. Screener showed about Rs 2.74 lakh crore before the rally. Market cap changes with the price, so check a live quote.
Should I buy, sell or hold Divi's Laboratories?
Ans. Univest does not recommend any security and cannot give personal advice. A record high after a sharp rally, a premium valuation and divided analyst opinion all argue for careful research. Review your goals and risk tolerance, and consult a SEBI-registered adviser.
